CEO Michael Mahoney highlighted the company’s exceptional performance in 2024, with operational sales growth of 23% in Q4 and 18.5% for the full year. Organic sales grew 20% in Q4, exceeding guidance.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Co. (PG), Boston ...

Q4 2024 Earnings Call Transcript February 5, 2025 Operator: Good morning, and welcome to the Boston Scientific Fourth Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is ...

Boston Scientific. "We have a strong foundation for growth, and I am incredibly grateful for our talented global team and the opportunity to continue transforming the lives of millions of patients ...

We recently compiled a list of the 10 Best Momentum Stocks to Buy According to Hedge Funds. In this article, we are going to ...

To calculate adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders ... Please refer to Part II, Item 7. Management's Discussion and Analysis ...

The GAAP financial measures most directly comparable to adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific ... schedules. Management uses these supplemental ...

Feb 5 (Reuters) - Medical device maker Boston Scientific (BSX.N), opens new tab forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.

Commanding a market cap of $150.9 billion, Boston Scientific Corporation (BSX) is a global medical device manufacturer that develops, manufactures, and markets a broad range of innovative products.